Explore All Access
Check if your research matches the topics covered in mAbs?
- Degree of match
- Common matching concepts
- Additional journal recommendations
mAbs : Impact Factor & More
eISSN: 1942-0870pISSN: 1942-0862
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Aims and Scope
mAbs is a peer-reviewed multi-disciplinary scientific journal established in 2009, published by Taylor & Francis and dedicated to the art and science of antibody research and development. Its editor-in-chief is Janice M. Reichert and it is affiliated with The Antibody Society. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider mAb community, including readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. It is indexed in MEDLINE, PubMed, the Science Citation Index Expanded, Biological Abstracts, BIOSIS Previews, and Scopus. Less
mAbs Key Metrics
CiteScore 
10.2
Eigenfactor
0.01 - 0.05
Impact Factor
5 - 10
SJR
Q1Immunology
SNIP
1.55
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months17%
4 to 6 months67%
7 to 9 months17%
Above 9 months0%
Did you find this useful?
Topics Covered on mAbs
Biosimilar
Monoclonal antibody
Immunoglobulin G
Heavy chain
Bispecific antibody
Dual targeting
Lymph node
Mass spectrometry
Central nervous system
Crystal structure
Antitumor response
Biopharmaceutical
High affinity binding
Phage display
Inflammatory arthritis
Protective antibody
Target antigen
Sequence analysis
Antigen binding
Tumor microenvironment
mAbs Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS INC |
| Language | English |
| Frequency | Bi-monthly |
| Article Processing Charges | GBP 2915 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2009 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in mAbs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in mAbs
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
- 31 Dec 2024
- mAbs
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
- 31 Dec 2024
- mAbs
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
- 31 Dec 2024
- mAbs
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
- 31 Dec 2024
- mAbs
Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations
- 31 Dec 2024
- mAbs
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
- 31 Dec 2024
- mAbs
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers
- 31 Dec 2024
- mAbs
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
- 31 Dec 2024
- mAbs
Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
- 31 Dec 2024
- mAbs
CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody
- 31 Dec 2024
- mAbs
Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations
- 31 Dec 2024
- mAbs
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
- 31 Dec 2024
- mAbs
Compare Similar Journals with mAbs
Select Journals to Compare with mAbs
Total journals - 9
You can select up to 3 Journals at a time
Frontiers in Immunology
Publisher: FRONTIERS MEDIA SA
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Antibodies
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
Immunology
Publisher: WILEY
International Journal of Molecular Sciences
Publisher: MDPI
Scientific Reports
Publisher: NATURE PORTFOLIO
Journal of Immunological Methods
Publisher: ELSEVIER
Blood
Publisher: AMER SOC HEMATOLOGY
Journal for ImmunoTherapy of Cancer
Publisher: BMJ PUBLISHING GROUP
0 Journals Selected to compare with
mAbs
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on mAbs
How long has mAbs been actively publishing? 
mAbs has been in operation since 2009 till date.
What is the publishing frequency of mAbs?
mAbs published with a Bi-monthly frequency.
How many articles did mAbs publish last year?
In 2023, mAbs publsihed 95 articles.
What is the eISSN & pISSN for mAbs?
For mAbs, eISSN is 1942-0870 and pISSN is 1942-0862.
What is Citescore for mAbs?
Citescore for mAbs is 10.2.
What is SNIP score for mAbs?
SNIP score for mAbs is 1.55.
What is the SJR for mAbs?
SJR for mAbs is Q1.
Who is the publisher of mAbs?
TAYLOR & FRANCIS INC is the publisher of mAbs.
